|
|
|
| home > white papers > The Promise and Challenge of Adaptive Design in Oncology Trials - Medpace |
|
|
 WHITE PAPERS |
|
Medpace
|
|
The Promise and Challenge of Adaptive Design in Oncology Trials
|
|
Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research.
Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Northway Biotechpharma enters into Development and Manufacturing Agreement with Synklino
Vilnius, Lithuania, and Copenhagen, Denmark – December 18th 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Synklino, a company active in developing a therapeutic protein based therapy as treatment for cytomegalovirus (CMV) infection, announced today that they entered into a Development and Manufacturing Agreement for the recombinant fusion protein SYNx, which Synklino aims to bring into clinical trials.
More info >> |
|
 |
White Papers |
 |
|
Keeping Abreast of the Competitive Environment in Clinical Development
Thomson Reuters
Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >> |
|
 |
Industry Events |
 |
INTERPHEX 2020
28-30 April 2020, Javits Center NYC
More info >> |
|
|
|
